Pimavanserin tartrate: Phase III started

Acadia began the double-blind, placebo-controlled, North American Phase III (020) trial to evaluate 40 mg oral pimavanserin for 6 weeks as adjunct to dopamine replacement therapy in 200 patients. Acad...